Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Ashish Kamat interviews Patrick Soon-Shiong about expanding ANKTIVA® (NAI) indications to include papillary-only BCG-unresponsive bladder cancer. Dr. Soon-Shiong highlights three-year data showing 82% ...

Weranja Ranasinghe discusses research on developing an immunohistochemistry (IHC) profile to predict response to BCG in non-muscle invasive bladder cancer (NMIBC). In this pilot study analyzing ...

(UroToday.com) The 2025 AUA annual meeting featured a prostate cancer session and a presentation by Dr. Madison Krischak discussing access to prostate cancer clinical trials in the VA and whether ...

ASCO 2025 Press Releases Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ...

Peter Clark presented results from the SunRISe-1 study at SESAUA 2025, evaluating TAR-200, an intravesical sustained-release gemcitabine system, in BCG-unresponsive high-risk non-muscle invasive ...

Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer ...

There are other non-infectious IUC-related adverse effects that occur the longer an indwelling urinary catheter (IUC), particularly a transurethral IUC, is used for bladder drainage. They include ...

Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Plenary Session on Saturday 26 th of April. Drs. Lara ...

Silke Gillessen Sommer presents the phase III PEACE-3 trial results, which evaluated the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC. The ...